0167-6997 - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 643

<< First< Prev

Page of 33

Next >Last >>

Select item 93954701.

Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients

Chao Li, Mengdong Zhang, Jianwen Wang, Xiaodong Zhang

Invest New Drugs. 2022; 40(5): 1164. Published online 2022 Jul 5. doi: 10.1007/s10637-022-01273-z

Corrects:: Invest New Drugs. 2022; 40(3): 660–667.

PMCID:: PMC9395470

Correction PDF–326K

Select item 98288532.

Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine

Haiqin Ping, Wenjun Yu, Xiaoming Gong, Xin Tong, Cheyu Lin, Zhaojun Chen, Caiyun Cai, Kai Guo, Hengning Ke

Invest New Drugs. 2022; 40(6): 1356. Published online 2022 Aug 27. doi: 10.1007/s10637-022-01296-6

Corrects:: Invest New Drugs. 2022; 40(6): 1173–1184.

PMCID:: PMC9828853

Correction PDF–325K

Select item 85872363.

Author Correction to: Advances in anti-BRAF therapies for lung cancer

Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

Invest New Drugs. 2021; 39(5): 1456. Published online 2021 Mar 1. doi: 10.1007/s10637-021-01092-8

Corrects:: Invest New Drugs. 2021; 39(3): 879–890.

PMCID:: PMC8587236

Correction PDF–123K

Select item 29536284.

Erratum to: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

Brigette B. Y. Ma, Vivian W. Y. Lui, Fan Fong Poon, S. C. Cesar Wong, Ka Fai To, Elaine Wong, Honglin Chen, Kwok Wai Lo, Qian Tao, Margaret Heung Ling Ng, Suk Hang Cheng, Anthony T. C. Chan

Invest New Drugs. 2010 Jun; 28(3): 361. Published online 2010 Feb 15. doi: 10.1007/s10637-010-9397-3

Corrects:: Invest New Drugs. 2010 Jun; 28(3): 326–333.

PMCID:: PMC2953628

Correction PDF–43K

Select item 68281055.

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Chigusa Morizane, Shunsuke Kondo, Nobumasa Mizuno, Kazuo Hara, Akira Sawaki, Satoshi Hashigaki, Nobuyuki Kimura, Mami Murakami, Emiko Ohki, Richard C. Chao, Masayuki Imamura

Invest New Drugs. 2019; 37(3): 591. Published online 2019 Mar 23. doi: 10.1007/s10637-019-00757-9

Corrects:: Invest New Drugs. 2013; 31(5): 1265–1274.

PMCID:: PMC6828105

Correction PDF–103K

Select item 40796796.

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Yu Sunakawa, Junji Furuse, Takuji Okusaka, Masafumi Ikeda, Fumio Nagashima, Hideki Ueno, Shuichi Mitsunaga, Kensei Hashizume, Yuichiro Ito, Yasutsuna Sasaki

Invest New Drugs. 2014; 32(2): 388. Published online 2013 Sep 3. doi: 10.1007/s10637-013-0021-1

Corrects:: Invest New Drugs. 2014; 32(1): 104–112.

PMCID:: PMC4079679

Correction PDF–52K

Select item 68280197.

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Katsuhiko Okubo, Takashi Nakakuma, Hirofumi Yamada, Kei Kimizuka, Tohru Higuchi, for the SBCCSG-36 investigators

Invest New Drugs. 2019; 37(3): 592–593. Published online 2019 Apr 25. doi: 10.1007/s10637-019-00773-9

Corrects:: Invest New Drugs. 2019; 37(3): 538–547.

PMCID:: PMC6828019

Correction PDF–300K

Select item 90985968.

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

Saiama N. Waqar, Clifford Robinson, Anthony J. Olszanski, Alexander Spira, Melissa Hackmaster, Luisa Lucas, Laura Sponton, Hulin Jin, Ursula Hering, Damien Cronier, Marianna Grinberg, Annick Seithel-Keuth, Ivan Diaz-Padilla, Jordan Berlin

Invest New Drugs. 2022; 40(3): 679. Published online 2022 Feb 28. doi: 10.1007/s10637-022-01226-6

Corrects:: Invest New Drugs. 2022; 40(3): 596–605.

PMCID:: PMC9098596

Correction PDF–347K

Select item 91727489.

Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer

Ari Nishimura, Akira Ono, Kazushige Wakuda, Takanori Kawabata, Michitoshi Yabe, Taichi Miyawaki, Eriko Miyawaki, Hiroaki Kodama, Naoya Nishioka, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Hideyuki Harada, Toshiaki Takahashi

Invest New Drugs. 2022; 40(2): 464. Published online 2021 Nov 8. doi: 10.1007/s10637-021-01198-z

Corrects:: Invest New Drugs. 2022; 40(2): 403–410.

PMCID:: PMC9172748

Correction PDF–326K

Select item 670796810.

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim, Howard A. Burris, III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, Patricia M. LoRusso

Invest New Drugs. 2017; 35(5): 669. Published online 2017 Jul 5. doi: 10.1007/s10637-017-0479-3

Corrects:: Invest New Drugs. 2017; 35(5): 576–588.

PMCID:: PMC6707968

Correction PDF–268K

Select item 899370711.

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study

Kyaw Z. Thein, Daniel D. Karp, Apostolia Tsimberidou, Jing Gong, Selma Sulovic, Jatin Shah, Denái R. Milton, David S. Hong, Filip Janku, Lacey McQuinn, Bettzy A. Stephen, Rivka Colen, Brett W. Carter, Timothy A. Yap, Sarina A. Piha‑Paul, Siqing Fu, Funda Meric‑Bernstam, Aung Naing

Invest New Drugs. 2022; 40(2): 463. Published online 2021 Nov 3. doi: 10.1007/s10637-021-01194-3

Corrects:: Invest New Drugs. 2022; 40(2): 290–299.

PMCID:: PMC8993707

Correction PDF–483K

Select item 544385012.

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, J. M. Stewart

Invest New Drugs. 2017; 35(3): 397. Published online 2017 Apr 7. doi: 10.1007/s10637-017-0455-y

Corrects:: Invest New Drugs. 2017; 35(3): 324–333.

PMCID:: PMC5443850

Correction PDF–177K

Select item 899372213.

Correction to: Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma

Nadire Özenver, Sara Abdelfatah, Anette Klinger, Edmond Fleischer, Thomas Efferth

Invest New Drugs. 2022; 40(2): 462. Published online 2021 Oct 27. doi: 10.1007/s10637-021-01193-4

Corrects:: Invest New Drugs. 2021; 39(2): 348–361.

PMCID:: PMC8993722

Correction PDF–502K

Select item 899372514.

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study

Kyaw Zin Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Abdulrazzak Zarifa, Jatin Shah, Denái R. Milton, Stacie Bean, Lacey McQuinn, Jing Gong, Rivka Colen, Brett W. Carter, Vivek Subbiah, Deby C. Ogbonna, Shubham Pant, Funda Meric-Bernstam, Aung Naing

Invest New Drugs. 2022; 40(2): 461. Published online 2021 Oct 27. doi: 10.1007/s10637-021-01192-5

Corrects:: Invest New Drugs. 2021; 39(5): 1357–1365.

PMCID:: PMC8993725

Correction PDF–501K

Select item 832982115.

Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Hiroto Inoue, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Kazuaki Yasui, Hirofumi Ogawa, Tsuyoshi Onoe, Masahiro Endo, Hideyuki Harada, Toshiaki Takahashi

Invest New Drugs. 2021; 39(3): 899. Published online 2020 Jun 26. doi: 10.1007/s10637-020-00969-4

Corrects:: Invest New Drugs. 2020; 38(5): 1612–1617.

PMCID:: PMC8329821

Correction PDF–137K

Select item 802527716.

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Frank Kroschinsky, Jan Moritz Middeke, Martin Janz, Georg Lenz, Mathias Witzens-Harig, Reda Bouabdallah, Paul La Rosée, Andreas Viardot, Gilles Salles, Seok Jin Kim, Tae Min Kim, Oliver Ottmann, Joerg Chromik, Anne-Marie Quinson, Ute von Wangenheim, Ute Burkard, Andreas Berk, Norbert Schmitz

Invest New Drugs. 2021; 39(1): 285–286. Published online 2020 Jun 23. doi: 10.1007/s10637-020-00964-9

Corrects:: Invest New Drugs. 2020; 38(5): 1472–1482.

PMCID:: PMC8025277

Correction PDF–159K

Select item 1116478917.

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Jr, Aaron R. Hansen, Jong-Seok Lee, Frank Tsai, Benjamin J. Solomon, Tae Min Kim, Christian Rolfo, Vincent Giranda, Yixin Ren, Fang Liu, Bhargava Kandala, Tomoko Freshwater, Judy S. Wang

Invest New Drugs. 2024; 42(3): 340–341. Published online 2024 May 20. doi: 10.1007/s10637-024-01444-0

Corrects:: Invest New Drugs. 2024; 42(1): 145–159.

PMCID:: PMC11164789

Correction PDF–506K

Select item 785285618.

Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi

Invest New Drugs. 2020; 38(6): 1846. Published online 2020 Sep 7. doi: 10.1007/s10637-020-00981-8

Corrects:: Invest New Drugs. 2020; 38(6): 1836–1845.

PMCID:: PMC7852856

Correction PDF–142K

Select item 325631419.

A short report on article by V. Pruliere-Escabasse et al., Vol. 27: 285–286, 2009

Terence M. Davidson

Invest New Drugs. 2012; 30(1): 423–424. Published online 2010 May 4. doi: 10.1007/s10637-010-9434-2

PMCID:: PMC3256314

Article PDF–51K

Select item 802526920.

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Invest New Drugs. 2021; 39(1): 283–284. Published online 2020 May 31. doi: 10.1007/s10637-020-00949-8

Corrects:: Invest New Drugs. 2020; 38(5): 1472–1482.

PMCID:: PMC8025269

Correction PDF–177K

<< First< Prev

Page of 33

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

Find related data

Search details

Recent activity

Clear Turn Off Turn On

0167-6997 (643)
PMC
Chain A, Diphtheria toxin repressor
Chain A, Diphtheria toxin repressor
gi|239781909|pdb|3GLX|A

Protein
iron repressor [Streptomyces coelicoflavus ZG0656]
iron repressor [Streptomyces coelicoflavus ZG0656]
gi|371543951|gb|EHN72711.1||gnl|WGS |SMCF_7866

Protein
acrB/AcrD/AcrF family protein [Vibrio cholerae HE48]
acrB/AcrD/AcrF family protein [Vibrio cholerae HE48]
gi|340049567|gb|EGR10481.1||gnl|WGS |VCHE48_0200

Protein
Homo sapiens HCF-binding transcription factor Zhangfei (ZF) mRNA, complete cds
Homo sapiens HCF-binding transcription factor Zhangfei (ZF) mRNA, complete cds
gi|4730928|gb|AF039942.1|

Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to: